EYLEA (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema
7:05 am Regeneron Pharms announces priority review acceptance by FDA for EYLEA sBLA; target action date of March 30, 2015
EYLEA (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema
REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Cramer: Workday, Netflix, Amazon Struggle as Momentum Lags
Jim Cramer's Top Stock Picks: CSCO LB REGN AAPL YHOO
Jim Cramer's 'Mad Money' Recap: Here's Where Money Managers Should Put Their Money
Cramer: Not too late to buy Regeneron
REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
UPDATE: Bank Of America Reiterates On Regeneron Pharmaceuticals Following Several Positive Catalysts
Fighting kids' cancer, one voucher at a time
New data fuels doctors' demands to rewrite U.S. heart guidelines
Sanofi touts new drugs but diabetes outlook disappoints
Regeneron & Sanofi Present Positive Data on PCSK9 Drug
Gilead to Buy Knight Therapeutics' Priority Review Voucher
Regeneron Shares Could Reach $450
Sanofi's Bullish Pipeline Forecast Underwhelms Street
Sanofi eyes more than $38 bln from new drugs after CEO exit
The Zacks Analyst Blog Highlights: Geron, Gilead, Regeneron, Celldex Therapeutics and AbbVie
Sanofi, Regeneron eczema drug gets FDA fast-track designation
Sanofi and Regeneron Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis
Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis
The Forbes Healthcare Summit 2014: The Agenda
Regeneron/Bayer's Eylea Gets Japanese Approval for DME
3 Drugs Stocks Driving The Industry Higher
Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
Stocks Boosted by Merck's Vytorin Data
Regeneron Announces EYLEA (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan
Sanofi's dual-action biotech asthma drug performs well in test
Sanofi's dual-action biotech asthma drug performs well in test
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
US STOCKS-Wall St slips as energy extends recent slide
Regeneron falls after paring Eylea sales outlook
US STOCKS-Futures point to lower open, energy shares in view
Regeneron Reports Third Quarter 2014 Financial and Operating Results
Regeneron Announces Upcoming 2014 Investor Conference Presentations
Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
EYLEA (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year
Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments
Regeneron to Report Third Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2014
Regeneron, Sanofi say sinusitis drug met goals
US STOCKS-Biotech shares drop, Amarin plunges 20 pct
US STOCKS-S&P 500 tops 2,000; analysts see more gains ahead
Sanofi lifts 2014 guidance after second quarter earnings beat expectations
US STOCKS-S&P 500, Nasdaq end up as Fed in no rush to raise rates
US STOCKS-S&P 500 nearly flat as investors digest Fed statement
US STOCKS-S&P 500 turns higher after Fed statement
Sanofi, Regeneron drug cuts cholesterol in nine late-stage trials
Sanofi raises stake in Regeneron; shares jump
Valeant injects cash into bid for Botox maker Allergan
Wall St Week Ahead - Momentum names may see more pain
Wall St Week Ahead - Momentum names may see more pain
Sanofi and Regeneron To Present Alirocumab Clinical Data at American College of Cardiology 63rd Annual Scientific Session
Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session
Wall Street rebounds; biotech shares snap losing streak
US close: Stocks suffer heavy losses despite strong US data
U.S. FDA probes cognitive impact of new cholesterol drugs
Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan
Regeneron Announces FDA Acceptance of EYLEA (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion
Regeneron Announces Upcoming 2014 Investor Conference Presentations
Regeneron Reports Fourth Quarter and Full Year 2013 Financial and Operating Results
Two-Year Results From Phase 3 VISTA Trial of EYLEA (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Regeneron to Report Fourth Quarter and Full Year 2013 Financial and Operating Results and Host Conference Call and Webcast on February 11, 2014
Regeneron rises on 4Q outlook for Eylea
US close: Dow, S&P 500 hit new records as jobless claims drop
Regeneron Pharmaceuticals Inc Stock Racks Up Another Win
Stock Watch: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7 Things Regeneron Pharmaceuticals Inc.'s Management Wants You to Know
Agree To Buy Regeneron Pharmaceuticals At $250, Earn 4.8% Using Options
Sanofi SA (SNY), Regeneron Pharmaceuticals (REGN) Eczema Drug Gets FDA ...
Regeneron Pharmaceuticals Offers More Upside Than Gilead Sciences
Regeneron Pharmaceuticals Has A Bright Future Ahead
Regeneron Pharmaceuticals (REGN) Flagged As Today's Pre-Market Laggard
Regeneron Pharmaceuticals (REGN) Stock Declines on Lower Eylea Revenue ...
There Is Further Upside Potential In Regeneron Pharmaceuticals
